Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07393672 · ClinicalTrials.gov registry record · Phase 2
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
A Phase 2 study of Menopause and Perimenopause, sponsored by Washington State University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT07393672: Recruiting Phase 2 study of Menopause and Perimenopause, sponsored by Washington State University.
NCT07393672 is a Phase 2 study of Menopause and Perimenopause that is actively recruiting participants, run by Washington State University. The registered enrollment target is 104 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07393672, a Phase 2 study of Menopause and Perimenopause, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Primary Outcome
At the end of each monthly Zoom session, participants will be sent a survey link including the Center for Epidemiologic Studies Depression Scale (CES-D). Participants will complete the CES-D after each zoom session, including the first session, the baseline session after four week, and after both phase 1 and phase 2.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hemp-derived cannabinoids
Study Locations (1)
Washington
- Washington State University, Dept of Psychology - Pullman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2026-11-10 |
| Phase | Phase 2 |
What NCT07393672 shows while recruiting
NCT07393672 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07393672 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT07393672 about?
NCT07393672 is a clinical study titled "Effects of Hemp-Derived Cannabinoids on Menopause Symptoms". The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
What is the current status of trial NCT07393672?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2026-02-11. Estimated completion is 2026-11-10.
What conditions does trial NCT07393672 study?
This clinical trial studies the following conditions: Menopause, Perimenopause.
What interventions are being tested in trial NCT07393672?
The interventions under investigation include: Placebo (DRUG), Hemp-derived cannabinoids (DRUG).
Who is sponsoring clinical trial NCT07393672?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07393672 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07393672's enrollment target sits among peer trials
104 18th of 54 higher than 37 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Impact of Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
ACTIVE NOT RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
COMPLETED · Phase 2
-
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI